NNVC – Breakout Potential Building

AwesomeStocks

*Read Disclaimer Sponsored Content | Unsubscribe

Hello!

Following our alert this morning, NNVC opened at 1.44.

So far, that is near the 1.47 high of the day, so no tangible gains yet.

Here are a couple of the things to keep in mind for upside potential.

Continue to watch for it to hold above its 200 day moving average of 1.39, that’s the first sign.

A rally and close above the 50 day moving average of 1.52 could result in increased upside. 

In addition, NNVC has a RSI of 48 – showing upside potential.

A close near the high and rally above the 50 day moving average could signal the beginning of the renewed breakout.

In July, the company traded as high as 1.79, +24% from today’s open.

Here are NNVC’s two recent announcements:

Today, they are presenting “at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025”.

As the company mentioned in this press release from last week:

“Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.”

In addition:

“Dr. Diwan has several pre-scheduled meetings in the partnering sessions and will also be available for meetings during the Congress on September 16th and 17th outside his busy schedule.”

The “LSX World Congress-USA is where innovators, investors and senior life science dealmakers in the LSX community connect, learn and partner.” 

“The Congress gathers leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership opportunities.”

“It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology.” 

“Empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare is the objective of LSX World Congress.”

As the company explained in August:

“A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials”

Importantly, from this press release:

“NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness.”

 

“This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known.”

 

“NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study.”

 

“In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387.”

 

“The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals.”

As more investors discover this company, they could notice what we believe to be an overlooked opportunity.

Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, Website, Chart

Happy Trading!

AwesomeStocks

Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.

DISCLAIMER

You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”).  The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov; the Financial Industry Regulatory Authority (the “FINRA”) at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated a total of eight thousand dollars by bank wire transfer on 6/20/25 for the distribution of this advertisement about NNVC dated 9/17/25. Previously, owners and operators of the Publisher have been compensated a total of eight thousand dollars by bank wire transfer on 6/20/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated seven thousand dollars by bank wire transfer on 2/20/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated seven thousand dollars by bank wire transfer on 1/8/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated four thousand dollars by bank wire transfer on 12/16/24 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand three hundred and thirty four dollars by bank wire transfer on 9/24/24 for the distribution of a prior advertisement about NNVC. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about NNVC. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this report/release because you subscribed to receive it at our website or through a third-party site.  All our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:

www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Our records indicate that postdailyrecap@gmail.com requested and confirmed to be added to AwesomeStocks.com on April 17, 2023. Click Here To Unsubscribe